Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis

被引：0
|
作者：
Sridhar Murahari
Aimee L. Jalkanen
Samuel K. Kulp
Ching-Shih Chen
Jaime F. Modiano
Cheryl A. London
William C. Kisseberth
机构：
[1] The Ohio State University,Department of Veterinary Clinical Sciences, College of Veterinary Medicine
[2] The Ohio State University,Department of Veterinary Biosciences, College of Veterinary Medicine
[3] The Ohio State University,Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy
[4] University of Minnesota,Department of Veterinary Clinical Sciences, College of Veterinary Medicine
[5] University of Minnesota,Masonic Cancer Center
[6] Colorado State University,Current address: Department of Microbiology, Immunology and Pathology
来源：
BMC Cancer | / 17卷
关键词：
Apoptosis; AR-42; Dog; Histone deacetylase inhibitor; Osteosarcoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
    Murahari, Sridhar
    Jalkanen, Aimee L.
    Kulp, Samuel K.
    Chen, Ching-Shih
    Modiano, Jaime F.
    London, Cheryl A.
    Kisseberth, William C.
    BMC CANCER, 2017, 17
  • [2] AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition
    Zhang, Mingming
    Pan, Yida
    Dorfman, R. G.
    Chen, Zhaogui
    Liu, Fuchen
    Zhou, Qian
    Huang, Shan
    Zhang, Jun
    Yang, Dongqin
    Liu, Jie
    ONCOTARGET, 2016, 7 (16) : 22285 - 22294
  • [3] AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma
    Zhu, Yuxuan
    Yuan, Ting
    Zhang, Yuan
    Shi, Jianyou
    Bai, Lan
    Duan, Xingmei
    Tong, Rongsheng
    Zhong, Lei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 4321 - 4330
  • [4] A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas
    Sborov, Douglas W.
    Canella, Alessandro
    Hade, Erinn M.
    Mo, Xiaokui
    Khountham, Soun
    Wang, Jiang
    Ni, Wenjun
    Poi, Ming
    Coss, Christopher
    Liu, Zhongfa
    Phelps, Mitch A.
    Mortazavi, Amir
    Andritsos, Leslie
    Baiocchi, Robert A.
    Christian, Beth A.
    Benson, Don M.
    Flynn, Joseph
    Porcu, Pierluigi
    Byrd, John C.
    Pichiorri, Flavia
    Hofmeister, Craig C.
    LEUKEMIA & LYMPHOMA, 2017, 58 (10) : 2310 - 2318
  • [5] Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer
    Li, David R.
    Zhang, Hanwei
    Peek, Elizabeth
    Wang, Song
    Du, Lin
    Li, Gang
    Chin, Arnold I.
    JOURNAL OF UROLOGY, 2015, 194 (02) : 547 - 555
  • [6] The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis
    Elshafae, Said M.
    Kohart, Nicole A.
    Altstadt, Lucas A.
    Dirksen, Wessel P.
    Rosol, Thomas J.
    PROSTATE, 2017, 77 (07) : 776 - 793
  • [7] Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP
    K Watanabe
    K Okamoto
    S Yonehara
    Cell Death & Differentiation, 2005, 12 : 10 - 18
  • [8] Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP
    Watanabe, K
    Okamoto, K
    Yonehara, S
    CELL DEATH AND DIFFERENTIATION, 2005, 12 (01) : 10 - 18
  • [9] Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation
    Tng, Jiahui
    Lim, Junxian
    Wu, Kai-Chen
    Lucke, Andrew J.
    Xu, Weijun
    Reid, Robert C.
    Fairlie, David P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (11) : 5956 - 5971
  • [10] Anti-oral Squamous Cell Carcinoma Effects of a Potent TAZ Inhibitor AR-42
    Su, Lingyu
    Wang, Si
    Yuan, Ting
    Xie, Xudong
    Fu, Xiaoming
    Ji, Ping
    Zhong, Lei
    Liu, Wenzhao
    JOURNAL OF CANCER, 2020, 11 (02): : 364 - 373
12345